Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0017337,
umls-concept:C0034790,
umls-concept:C0038402,
umls-concept:C0039195,
umls-concept:C0080032,
umls-concept:C0205263,
umls-concept:C0330390,
umls-concept:C0457083,
umls-concept:C0595451,
umls-concept:C0918027,
umls-concept:C1521827,
umls-concept:C1979963,
umls-concept:C2003903
|
| pubmed:issue |
4
|
| pubmed:dateCreated |
1998-1-30
|
| pubmed:abstractText |
T-cell receptor (TCR) gene rearrangements were analyzed in tumor-infiltrating lymphocytes (TIL) using the reverse transcription-polymerase chain reaction (RT-PCR) to determine whether oligoclonal expression of TCRV beta occurs in TIL, and if so, whether it is involved in the clinical response and mechanisms of locoregional immunotherapy using a streptococcal preparation, OK432. Patients with malignant effusion of various origins were treated with intrapleural administration of OK432, and clinical responses were assessed by cytological and chest X-ray examinations. Pleural exudate cells (PEC), obtained before and after the administration of OK432 (designated as pre- and OK432-PEC, respectively), were subjected to TCR analysis. Both pre-PEC and OK432-PEC showed highly diverse expressions of TCRV beta gene usage in either type of PEC. The frequency of TCRV beta 20 gene expression in OK432-PEC was significantly higher than in pre-PEC. Moreover, the over-expression of the TCRV beta 20 gene usage was also induced in the peripheral blood lymphocytes and pre-PEC of patients by in vitro OK432 stimulation, but not in the PBL of one healthy volunteer. Single-strand conformational polymorphism (SSCP) analysis revealed the clonotypes of these TCRV beta 20 genes. Autologous tumor-specific killing activity could be detected in OK432-PEC and was significantly reduced by treatment with a TCRV beta 20-specific monoclonal antibody. These findings suggest that the rearrangement of TCRV beta 20 gene usage may be involved in the autologous tumor-specific action of malignant effusions in the treatment with OK432.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1359-4117
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
242-50
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9414411-Aged,
pubmed-meshheading:9414411-Antineoplastic Agents,
pubmed-meshheading:9414411-Blotting, Southern,
pubmed-meshheading:9414411-Female,
pubmed-meshheading:9414411-Genes, T-Cell Receptor beta,
pubmed-meshheading:9414411-Humans,
pubmed-meshheading:9414411-Immunotherapy,
pubmed-meshheading:9414411-Injections,
pubmed-meshheading:9414411-Male,
pubmed-meshheading:9414411-Middle Aged,
pubmed-meshheading:9414411-Phenotype,
pubmed-meshheading:9414411-Picibanil,
pubmed-meshheading:9414411-Pleura,
pubmed-meshheading:9414411-Pleural Effusion, Malignant,
pubmed-meshheading:9414411-Polymerase Chain Reaction,
pubmed-meshheading:9414411-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:9414411-RNA Probes,
pubmed-meshheading:9414411-T-Lymphocytes, Cytotoxic
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Profile of T-cell receptor V beta gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions.
|
| pubmed:affiliation |
Department of Surgical Oncology, Hiroshima University, Japan.
|
| pubmed:publicationType |
Journal Article
|